116
+4.50%
Close of 9 Nov 2026, in JPY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About StemRIM
Its shares trade on Tokyo Stock Exchange under the ticker 4599.T. It has been listed since 9 August 2019. In the fiscal year to 31 July 2023, it reported revenue of ¥2.35bn and net income of ¥168.3m. At that date it held total assets of ¥10.72bn and shareholders' equity of ¥10.37bn.
StemRIM, Inc. engages in the research and development of regeneration inducing medicine. The company is headquartered in Ibaraki-Shi, Osaka-Fu. The company went IPO on 2019-08-09. The firm is engaged in the development and research of medicines based on new action mechanism to promote functional regeneration and healing of biological tissue damaged and lost function due to injury or illness. The Company’s main product is stem cell regeneration-inducing medicine. The stem cell regeneration-inducing medicine is a medicine which can obtain the same therapeutic effect as regenerative medicine only by administering the medicine without using living cells and tissues.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 9 Aug 2019
- Employees
- 44
- Website
- stemrim.com ↗
Leadership
Pay as last reported
- Mr. Kensuke TomitaChairman of the Board, since 2013
- Mr. Masatsune OkajimaPresident, Chief Executive Officer, Representative Director, since 2019
- Mr. Takehiko YamazakiExecutive Officer, Director of Intellectual Property, since 2019
- Mr. Katsuto TamaiCSO, Director, since 2007
- Mr. Tadahiro NagaiIndependent Director
- Ms. Noriko SawaiIndependent Director
- Mr. Shuhei UematsuIR Contact Officer, since 2022
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Headquartered in Ibaraki-shi, Japan, with a focus on biotechnology within the healthcare sector.
- Operates with 44 full-time employees, indicating a lean organizational structure.
- Develops stem cell regeneration-inducing medicine, a unique product with a novel therapeutic mechanism.
Weaknesses
- Limited employee count of 44 may constrain research and development capacity.
- IPO occurred in 2019, suggesting a relatively young company with limited market history.
- Reliance on a single main product, stem cell regeneration-inducing medicine, increases business risk.
Opportunities
- Growing global demand for regenerative medicine solutions could expand market reach.
- Potential for partnerships with larger pharmaceutical companies to enhance R&D capabilities.
- Advancements in biotechnology may improve the efficacy and application of their medicine.
Threats
- Competition from established pharmaceutical firms in the regenerative medicine sector.
- Regulatory hurdles in developing and commercializing new medical treatments.
- Dependence on a single product may lead to significant financial vulnerability if market acceptance is low.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.